Extremely Low LDL: Friend or Foe? – Cardiovascular Outcomes, Safety & New Evidence | Dr. Mahesh Shah

How low is too low when it comes to LDL? With newer potent lipid-lowering therapies, clinicians are increasingly encountering patients with extremely low LDL levels — but the clinical implications aren't always straightforward. In this Medflix session, Dr. Mahesh Shah breaks down the physiology, safety data, and real-world decision-making around aggressive LDL reduction.

Learn about:
🩺 What defines “very low” and “extremely low” LDL levels
📉 Do ultra-low LDL levels increase risks — hemorrhagic stroke, diabetes, cognition issues?
💊 Impact of statins, PCSK9 inhibitors & combination therapy
🧬 Understanding LDL in inflammation, immunity & endothelial health
📚 Key evidence from FOURIER, IMPROVE-IT & ODYSSEY trials
🩻 Practical decisions: when to intensify, when to stop, and how to monitor

🎯 A must-watch for Cardiologists, Internists, Physicians & GPs.

⏱️ Chapters:
0:00 Introduction – Why extremely low LDL is a hot topic
2:10 Physiology of LDL: What does LDL actually do?
5:40 What is “very low” vs “extremely low” LDL?
8:15 Cardiovascular benefits of aggressive LDL lowering
12:30 Safety concerns: cognition, diabetes, hemorrhagic stroke
16:55 Evidence review: FOURIER, ODYSSEY, IMPROVE-IT
22:40 Statins vs PCSK9 inhibitors – how low do they take LDL?
27:10 Clinical scenarios: when LDL drops less than 20 mg/dL
31:20 When to intensify vs de-escalate lipid therapy
35:45 Monitoring: lipids, LFTs, glucose & risk profiling
39:10 Case discussions
44:00 Key takeaways

👉 Don’t forget to install Medflix for more such expert-led sessions
🌐 www.medflix.app/app

#LDL #Cholesterol #LipidManagement #Cardiology #HeartHealth #Statins #PCSK9 #Atherosclerosis #Medflix #ClinicalEducation #CardiovascularRisk #FOURIERTrial #ODYSSEYTrial #CholesterolFacts